GHRH Agonists Significantly Shrink Heart Attack Scars in Pigs
Background
Ischemic cardiomyopathy is a severe heart condition resulting from damage to the heart muscle due to reduced blood flow, often following a myocardial infarction (heart attack). This damage leads to scar tissue formation, which impairs the heart's pumping ability and can cause heart failure. Current treatments primarily manage symptoms, but there's a critical need for therapies that can directly reduce scar tissue and improve heart function. This study specifically addresses whether growth hormone-releasing hormone (GHRH) agonists can reduce infarct scar and improve cardiac function in a large animal model of subacute ischemic cardiomyopathy.
Results
Treatment with MR-401 significantly improved cardiac health and reduced scar tissue in the swine model. > The high-dose 30 μg/kg/d MR-401 group showed a remarkable 43% reduction in myocardial infarct scar mass compared to controls, while the 10 μg/kg/d group achieved a 33% reduction (all p<0.05). Both doses also significantly improved left ventricular ejection fraction (LVEF), a key measure of heart pumping ability, by 10% (10 μg/kg/d) and 12% (30 μg/kg/d) respectively, compared to control animals. Furthermore, MR-401 reduced left ventricular end-diastolic volume (LVEDV) by up to 20% and left ventricular end-systolic volume (LVESV) by up to 25%, indicating less heart dilation and improved contractility. The treatment also increased myocardial viability by up to 16%, boosted capillary density by 3-fold, and arteriolar density by 2-fold, suggesting enhanced blood vessel formation (angiogenesis) and reduced myocardial fibrosis by up to 30%.
Why It Matters
This study provides compelling evidence that GHRH agonists can significantly reduce heart attack scar tissue and improve heart function in a large animal model, offering a novel therapeutic strategy for ischemic cardiomyopathy. The ability to directly reduce scar mass, enhance cardiac performance, and promote angiogenesis represents a major advancement over current symptomatic treatments. These findings strongly support the potential for GHRH agonists to be developed into a new class of drugs for patients suffering from heart failure post-myocardial infarction. Future steps should include further preclinical validation and progression to human clinical trials (e.g., Phase I/II) to assess safety and efficacy in patients.